How the study was conducted
Investigators compared adults taking semaglutide or liraglutide with those prescribed older weight-loss pills.
Participants were tracked for at least 12 months, and emergency visits plus hospitalizations were counted as endpoints.
Key clinical findings
Patients on GLP-1 drugs were significantly more likely to develop stomach paralysis that required feeding tubes or surgery.
Researchers also documented higher rates of biliary disease and intestinal ischemia in younger users.
- Risk remained elevated even after adjusting for diabetes
- Women under 45 recorded the fastest rise in ER visits
- Average time to first complication was five months
Implications for litigation
These numbers support failure-to-warn claims now pending in MDL 3094.
Experts expect defendants to face Daubert challenges if they attempt to discredit the peer-reviewed methodology.
What patients can do now
Share the JAMA article with treating physicians so symptoms are promptly coded and reported.
Track digestive complaints in a journal to show how daily life and employment were disrupted.
Why the study matters
- First large cohort tying GLP-1 weight-loss use to gastroparesis
- Shows injuries are not limited to diabetic patients
- Provides statistical backing for punitive damages arguments